These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 9435906

  • 1. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y, Chackalamannil S, Czarniecki M, Tsai H, Vaccaro H, Cleven R, Cook J, Fawzi A, Watkins R, Zhang H.
    J Med Chem; 1997 Dec 19; 40(26):4372-7. PubMed ID: 9435906
    [Abstract] [Full Text] [Related]

  • 2. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
    Ahn HS, Bercovici A, Boykow G, Bronnenkant A, Chackalamannil S, Chow J, Cleven R, Cook J, Czarniecki M, Domalski C, Fawzi A, Green M, Gündes A, Ho G, Laudicina M, Lindo N, Ma K, Manna M, McKittrick B, Mirzai B, Nechuta T, Neustadt B, Puchalski C, Pula K, Zhang H.
    J Med Chem; 1997 Jul 04; 40(14):2196-210. PubMed ID: 9216839
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 4. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA, Asberom T, Boyle CD, Chackalamannil S, Chintala M, Clader JW, Greenlee WJ, Hu Y, Kurowski S, Myers J, Palamanda J, Stamford AW, Vemulapalli S, Wang Y, Wang P, Wu P, Xu R.
    Bioorg Med Chem Lett; 2004 Mar 08; 14(5):1291-4. PubMed ID: 14980684
    [Abstract] [Full Text] [Related]

  • 5. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, Pissarnitski DA, Stamford AW, Wang Y, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2365-9. PubMed ID: 15837326
    [Abstract] [Full Text] [Related]

  • 6. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A.
    Eur J Pharmacol; 2007 Mar 08; 558(1-3):107-12. PubMed ID: 17207788
    [Abstract] [Full Text] [Related]

  • 7. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
    Silver PJ, Dundore RL, Bode DC, de Garavilla L, Buchholz RA, van Aller G, Hamel LT, Bacon E, Singh B, Lesher GY.
    J Pharmacol Exp Ther; 1994 Dec 08; 271(3):1143-9. PubMed ID: 7996419
    [Abstract] [Full Text] [Related]

  • 8. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudinière R.
    J Med Chem; 2003 Oct 09; 46(21):4533-42. PubMed ID: 14521415
    [Abstract] [Full Text] [Related]

  • 9. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun 09; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 10. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
    Kapui Z, Schaeffer P, Mikus EG, Boronkay E, Gyürky J, Herbert JM, Pascal M.
    Arzneimittelforschung; 1999 Aug 09; 49(8):685-93. PubMed ID: 10483515
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G, Li J, Peng A, Lai S, Zhang S, Shen J, Liu Z, Chen X, Ji R.
    Bioorg Med Chem Lett; 2005 Jun 02; 15(11):2790-4. PubMed ID: 15878277
    [Abstract] [Full Text] [Related]

  • 12. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J, Giovannoni MP, Vergelli C, Gavaldà A, Cesari N, Graziano A, Dal Piaz V.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2381-4. PubMed ID: 15837329
    [Abstract] [Full Text] [Related]

  • 13. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
    Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.
    J Med Chem; 2006 Jun 15; 49(12):3581-94. PubMed ID: 16759100
    [Abstract] [Full Text] [Related]

  • 14. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J, Markerink-van Ittersum M, Vles JS.
    J Chem Neuroanat; 2006 Jun 15; 31(4):275-303. PubMed ID: 16621445
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
    Jiang W, Alford VC, Qiu Y, Bhattacharjee S, John TM, Haynes-Johnson D, Kraft PJ, Lundeen SG, Sui Z.
    Bioorg Med Chem; 2004 Mar 15; 12(6):1505-15. PubMed ID: 15018924
    [Abstract] [Full Text] [Related]

  • 16. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
    Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Kirilovsky J, Hyafil F, Labaudinière R.
    J Med Chem; 2003 Oct 09; 46(21):4525-32. PubMed ID: 14521414
    [Abstract] [Full Text] [Related]

  • 17. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
    Murray F, MacLean MR, Pyne NJ.
    Br J Pharmacol; 2002 Dec 09; 137(8):1187-94. PubMed ID: 12466227
    [Abstract] [Full Text] [Related]

  • 18. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI, Pagès L, Vega A, Segarra V, López M, Doménech T, Miralpeix M, Beleta J, Ryder H, Palacios JM.
    J Med Chem; 1998 Oct 08; 41(21):4021-35. PubMed ID: 9767640
    [Abstract] [Full Text] [Related]

  • 20. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M, Pekkinen M, Huttunen M, Lamberg-Allardt C.
    Cell Mol Biol Lett; 2005 Oct 08; 10(2):305-19. PubMed ID: 16010295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.